ERBB2 and breast carcinoma: FABULOUS study (35) evaluated the PARP inhibitor Fluzuloparib, both as monotherapy and in combination with Apatinib, versus investigator’s choice of chemotherapy in patients with germline BRCA-mutated, HER2-negative breast cancer.